162
Participants
Start Date
June 30, 2024
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
TQA3038 injection/placebo
TQA3038 is a Anti-Hepatitis B virus (HBV) drugs.
Nucleotide drugs Control group
Nucleotide drugs are nucleoside reverse transcriptase inhibitors.
The sixth people's hospital at of Shenyang, Shenyang
Shengjing Hospital Affiliated to China Medical University, Shenyang
The first hospital of Jilin University, Changchun
Hepatobiliary Hospital of Jilin, Changchun
The Fourth Affiliated Hospital of Harbin Medical University, Harbin
Shanghai Tongren Hospital, Shanghai
The First Affiliated Hospital of Bengbu Medical College, Bengbu
Shandong Public Health Clinical Center, Jinan
People's Hospital of Tianjin (City), Tianjin
The First Affiliated Hospital of Nanchang University, Nanchang
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou
The Southwest Hospital of AMU, Chongqing
The Second Affilated Hospital of Chongqing medical university, Chongqing
Xiangya Third Hospital of Central of Central Suoth University, Changsha
Tongji Hospital of Tongji medical college of HUST, Wuhan
Shiyan City Taihe Hospital, Shiyan
The Third Affiliated Hospital of Sun Yat sen University, Guangzhou
The First Affiliated Hospital of GUANGXI Medical University, Nanning
Guizhou Provincial People's Hospital, Guiyang
West China Hospital of Sichuan University, Chengdu
Gansu province people hospital, Lanzhou
The First Affiliated Hospital of Xinjiang Medical University, Ürümqi
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY